General Information of Drug (ID: DMH6GLU)

Drug Name
TAK-754 Drug Info
Synonyms BAX 888
Indication
Disease Entry ICD 11 Status REF
Haemophilia A 3B10.0 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMH6GLU

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor VIII (F8) TT1290U FA8_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Coagulation factor VIII (F8) DTT F8 7.637 6.9 7.644 6.975
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Haemophilia A
ICD Disease Classification 3B10.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor VIII (F8) DTT F8 1.08E-22 0.89 1.82
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03370172) A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion. U.S.National Institutes of Health.
2 A reprieve from hemophilia A, but for how long? Nat Biotechnol. 2020 Oct;38(10):1107-1109.